Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150

Emerging immunotherapy for HCC: A guide for hepatologists

(2022) Friedrich Foerster et al.   HEPATOLOGY

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

(2021) Dominik Pfister et al.   NATURE

Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020)

(2021) Philipp K. Haber et al.   GASTROENTEROLOGY

Hepatocellular Carcinoma — Origins and Outcomes

(2021) Robin K. Kelley et al.   NEW ENGLAND JOURNAL OF MEDICINE

mRECIST for HCC: Performance and novel refinements

(2020) Josep M. Llovet et al.   JOURNAL OF HEPATOLOGY

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Steatohepatitis Impairs T cell-directed Immunotherapies Against Liver Tumors in Mice

(2020) Bernd Heinrich et al.   GASTROENTEROLOGY

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

(2018) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY